How to buy Genetron stock | $21.17

Genetron Holdings Limited is a diagnostics & research business based in the US. Genetron shares (GTH) are listed on the NASDAQ and all prices are listed in US Dollars. Genetron employs 799 staff and has a trailing 12-month revenue of around 0.00.

Genetron stock price (NASDAQ: GTH)

Use our graph to track the performance of GTH stocks over time.

Genetron shares at a glance

• Key figures

Information last updated 2021-07-23.

Latest market close	$21.17
52-week range	$9.03 - $31.54
50-day moving average	$19.99
200-day moving average	$21.44
Wall St. target price	$26.06
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-4.56

Buy Genetron shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Genetron stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Genetron Holdings Limited by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Genetron price performance over time

Historical closes compared with the close of $21.17 from 2021-05-28

1 week (2021-07-19)	N/A
1 month (2021-06-30)	5.11%
3 months (2021-04-30)	0.05%
6 months (2021-01-26)	N/A

1 year (2020-07-26)	N/A
2 years (2019-07-26)	N/A
3 years (2018-07-26)	N/A
5 years (2016-07-26)	N/A

Genetron financials

Revenue TTM	$439.7 million
Gross profit TTM	$260.2 million
Return on assets TTM	-14.48%
Return on equity TTM	-2433.48%
Profit margin	0%
Book value	$17.40
Market capitalisation	$1.6 billion

TTM: trailing 12 months

Shorting Genetron shares

There are currently 376,491 Genetron shares held short by investors – that's known as Genetron's "short interest". This figure is 18.1% down from 459,618 last month.

There are a few different ways that this level of interest in shorting Genetron shares can be evaluated.

Genetron's "short interest ratio" (SIR)

Genetron's "short interest ratio" (SIR) is the quantity of Genetron shares currently shorted divided by the average quantity of Genetron shares traded daily (recently around 230976.07361963). Genetron's SIR currently stands at 1.63. In other words for every 100,000 Genetron shares traded daily on the market, roughly 1630 shares are currently held short.

However Genetron's short interest can also be evaluated against the total number of Genetron shares, or, against the total number of tradable Genetron shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Genetron's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Genetron shares in existence, roughly 0 shares are currently held short) or 0.0122% of the tradable shares (for every 100,000 tradable Genetron shares, roughly 12 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Genetron.

Find out more about how you can short Genetron stock.

Genetron share dividends

We're not expecting Genetron to pay a dividend over the next 12 months.

Genetron overview

Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early liver cancer screening services through laboratory developed tests services, such as HCCscreen, a proprietary assay for the early screening of hepatocellular carcinoma. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product based on semiconductor sequencing to detect lung cancer; Genetron 3D biochip reading instrument; IDH1 and TERT gene assays for glioma; Genetron S5 platform, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; and Genetron S2000 platform, a production-scale sequencer. In addition, the company develops ctDNA lung cancer assay for mutations in the epidermal growth factor receptor gene. Further, it offers development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies, hospitals, and research institutions worldwide. The company has a strategic partnership with JD Health to create solutions for full-cycle cancer management. Genetron Holdings Limited was founded in 2015 and is headquartered in Beijing, the People's Republic of China.

Frequently asked questions

What percentage of Genetron is owned by insiders or institutions?
Currently 16.032% of Genetron shares are held by insiders and 24.726% by institutions. How many people work for Genetron?
Latest data suggests 799 work at Genetron. When does the fiscal year end for Genetron?
Genetron's fiscal year ends in December. Where is Genetron based?
Genetron's address is: Building 11, Beijing, China, 102206 What is Genetron's ISIN number?
Genetron's international securities identification number is: US37186H1005